Bugs, stool, and the irritable bowel syndrome: Too much is as bad as too little?

Gastroenterology

Volumn 141, Issue 5, 2011, Pages 1555-1559

  Talley, Nicholas J ^a,b,c,d   Fodor, Anthony A ^e  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; RNA 16S; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ANTIBIOTIC THERAPY; ANXIETY; BLOATING; CONSTIPATION; DEPRESSION; DIARRHEA; EDITORIAL; FATIGUE; FECES; GEL ELECTROPHORESIS; HUMAN; IRRITABLE COLON; MICROBIOME; MICROFLORA; PAINFUL DEFECATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEOBACTERIA;

EID: 80054855719     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.09.019     Document Type: Editorial

References (27)

1. Talley NJ, Spiller R. Irritable bowel syndrome: a little understood organic bowel disease? Lancet 2002;360:555-564.
2. Rey E, Talley NJ. Irritable bowel syndrome: novel views on the epidemiology and potential risk factors. Dig Liver Dis 2009;41:772-780.
3. Koloski NA, Talley NJ, Boyce PM. The impact of functional gastrointestinal disorders on quality of life. Am J Gastroenterol 2000;95:67-71.
4. Brandt LJ CW, Foxx-Orenstein AE, Schiller LR, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104:S1-35.
5. Ford AC, Talley NJ, Veldhuyzen van Zanten SJO, et al. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? JAMA 2008;300:1793-1805.
6. Villani A-C, Lemire M, Thabane M, et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 2010;138:1502-1513.
7. Choung RS, Locke GR III, Zinsmeister AR, et al. Psychosocial distress and somatic symptoms in community subjects with irritable bowel syndrome: a psychological component is the rule. Am J Gastroenterol 2009;104:1772-1779.
8. Ford A, Talley N. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol 2011;46:421-431.
9. Walker M, Warwick A, Ung C, et al. The role of eosinophils and mast cells in intestinal functional disease. Curr Gastroenterol Rep 2011;13:323-330.
10. Cremon C, Carini G, Wang B, et al. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol 2011;106:1290-1298.
11. Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007;132:913-920.
12. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009;136:1979-1988.
13. Sekirov I, Finlay BB. Human and microbe: united we stand. Nat Med 2006;12:736-737.
14. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009;457:480-484.
15. Spencer MD, Hamp TJ, Reid RW, et al. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 2011;140:976-986.
16. Salonen A, de Vos WM, Palva A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology 2010;156:3205-3215.
17. Saulnier D, Riehle K, Mistretta T, et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 2011;141:1782-1791.
18. Rajilić-Stojanović M, Biagi E, Heilig HG, et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011;141:1792-1801.
19. Carroll IM, Ringel-Kulka T, Keku TO, et al. Molecular analysis of the luminal and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2011 July 7 [Epub ahead of print].
20. Adam B, Liebregts T, Gschossmann JM, et al. Severity of mucosal inflammation as a predictor for alterations of visceral sensory function in a rat model. Pain 2006;123:179-186.
21. Leek JT, Scharpf RB, Bravo HC, et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet 2010;11:733-739.
22. Zhou J, Wu L, Deng Y, et al. Reproducibility and quantitation of amplicon sequencing-based detection. ISME J 2011;5:1303-1313.
23. Boulesteix A-L. Over-optimism in bioinformatics research. Bioinformatics 2010;26:437-439.
24. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010;59:325-332.
25. Brenner DM, Moeller MJ, Chey WD, et al. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009;104:1033-1049.
26. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with Irritable Bowel Syndrome without constipation. N Engl J Med 2011;364:22-32.
27. Mendall MA KD. Antibiotic use, childhood affluence and irritable bowel syndrome. Eur J Gastroenterol Hepatol 1998;10:59-62.